Circulating oxidized low density lipoprotein levels - A biochemical risk marker for coronary heart disease

被引：315

作者：

Toshima, S

Hasegawa, A

Kurabayashi, M

Itabe, H

Takano, T

Sugano, J

Shimamura, K

Kimura, J

Michishita, I

Suzuki, T

Nagai, R

机构：

[1] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan

[2] Gunma Univ, Sch Med, Dept Internal Med 2, Gunma, Japan

[3] Saiseikai Maebashi Hosp, Dept Internal Med, Gunma, Japan

[4] Gunma Chuoh Gen Hosp, Dept Internal Med, Gunma, Japan

[5] Teikyo Univ, Fac Pharmaceut Sci, Dept Microbiol & Mol Pathol, Sagamiko, Kanagawa 19901, Japan

[6] Vessel Res Lab Co Ltd, Kanagawa, Japan

[7] Yokohama Sakae Kyosai Hosp, Dept Internal Med, Kanagawa, Japan

来源：

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2000年 / 20卷 / 10期

关键词：

oxidized low density lipoprotein; coronary heart disease; risk factors;

D O I：

10.1161/01.ATV.20.10.2243

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent studies have established oxidative modification of low density lipoprotein (LDL) as an important atherogenic factor. We examined the clinical relevance of circulating oxidized LDL (OxLDL) levels in atherosclerotic disease by an enzyme immunoassay with use of specific antibodies against OxLDL (FOH1a/DLH3) and apolipoprotein B, Plasma OxLDL levels were significantly higher in patients with coronary heart disease (n=65) than in control subjects (n=181; 201.3+/-11.2 versus 112.4+/-3.3 U/dL, respectively; P<0.01). OxLDL levels were not associated with age, sex, total cholesterol, or apolipoprotein B levels in normal control subjects. Our results suggest that circulating OxLDL may be a possible biochemical risk marker for coronary heart disease.

引用

收藏

页码：2243 / 2247

页数：5

相关论文

共 31 条

[1] ATHEROSCLEROSIS - BASIC MECHANISMS - OXIDATION, INFLAMMATION, AND GENETICS [J].

BERLINER, JA ;

NAVAB, M ;

FOGELMAN, AM ;

FRANK, JS ;

DEMER, LL ;

EDWARDS, PA ;

WATSON, AD ;

LUSIS, AJ .

CIRCULATION, 1995, 91 (09) :2488-2496

[2] MINIMALLY MODIFIED LOW-DENSITY-LIPOPROTEIN STIMULATES MONOCYTE ENDOTHELIAL INTERACTIONS [J].

BERLINER, JA ;

TERRITO, MC ;

SEVANIAN, A ;

RAMIN, S ;

KIM, JA ;

BAMSHAD, B ;

ESTERSON, M ;

FOGELMAN, AM .

JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (04) :1260-1266

[3] Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis [J].

Bui, MN ;

Sack, MN ;

Moutsatsos, G ;

Lu, DY ;

Katz, P ;

McCown, R ;

Breall, JA ;

Rackley, CE .

AMERICAN HEART JOURNAL, 1996, 131 (04) :663-667

[4] 7-BETA-HYDROPEROXYCHOLEST-5-EN-3-BETA-OL, A COMPONENT OF HUMAN ATHEROSCLEROTIC LESIONS, IS THE PRIMARY CYTOTOXIN OF OXIDIZED HUMAN LOW-DENSITY-LIPOPROTEIN [J].

CHISOLM, GM ;

MA, GP ;

IRWIN, KC ;

MARTIN, LL ;

GUNDERSON, KG ;

LINBERG, LF ;

MOREL, DW ;

DICORLETO, PE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (24) :11452-11456

[5] MINIMALLY MODIFIED LOW-DENSITY-LIPOPROTEIN INDUCES MONOCYTE CHEMOTACTIC PROTEIN-1 IN HUMAN ENDOTHELIAL-CELLS AND SMOOTH-MUSCLE CELLS [J].

CUSHING, SD ;

BERLINER, JA ;

VALENTE, AJ ;

TERRITO, MC ;

NAVAB, M ;

PARHAMI, F ;

GERRITY, R ;

SCHWARTZ, CJ ;

FOGELMAN, AM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (13) :5134-5138

[6] Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins - Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation [J].

Deckert, V ;

Persegol, L ;

Viens, L ;

Lizard, G ;

Athias, A ;

Lallemant, C ;

Gambert, P ;

Lagrost, L .

CIRCULATION, 1997, 95 (03) :723-731

[7] BINDING-SITE ON MACROPHAGES THAT MEDIATES UPTAKE AND DEGRADATION OF ACETYLATED LOW-DENSITY LIPOPROTEIN, PRODUCING MASSIVE CHOLESTEROL DEPOSITION [J].

GOLDSTEIN, JL ;

HO, YK ;

BASU, SK ;

BROWN, MS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (01) :333-337

[8]

HAMILTON TA, 1990, J IMMUNOL, V144, P2343

[9] Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease [J].

Holvoet, P ;

Vanhaecke, J ;

Janssens, S ;

Van de Werf, F ;

Collen, D .

CIRCULATION, 1998, 98 (15) :1487-1494

[10]

Holvoet P, 1996, THROMB HAEMOSTASIS, V76, P663

← 1 2 3 4 →